Update on typical and atypical antipsychotic drugs

Annual Review of Medicine

Volumn 64, Issue , 2013, Pages 393-406

  Meltzer, Herbert Y ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

antipsychotic; clozapine; cognition; extrapyramidal; metabolic; psychosis; schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ASENAPINE; ATYPICAL ANTIPSYCHOTIC AGENT; BLONANSERINE; CARIPRAZINE; CHLORPROMAZINE; CLOZAPINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; ILOPERIDONE; LURASIDONE; MELPERONE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PERPHENAZINE; PROLACTIN; QUETIAPINE; RISPERIDONE; SEROTONIN 2A RECEPTOR; UNCLASSIFIED DRUG; ZIPRASIDONE; ZOTEPINE;

AGRANULOCYTOSIS; BREAST CANCER; COGNITION; CONSTIPATION; DEMENTIA; DOPAMINE RELEASE; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG USE; DRUG WITHDRAWAL; DYSPHORIA; EOSINOPHILIA; EXTRAPYRAMIDAL SYMPTOM; FEVER; GALACTORRHEA; GYNECOMASTIA; HUMAN; HYPERLIPIDOSIS; HYPERPROLACTINEMIA; HYPERSALIVATION; ILEUS; MYOCARDITIS; NEUROLEPTIC MALIGNANT SYNDROME; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOPOROSIS; POSITIVE SYNDROME; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SWEATING; TARDIVE DYSKINESIA; TREATMENT DURATION; TREATMENT RESISTANT SCHIZOPHRENIA; URINE INCONTINENCE; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; COGNITION; HUMANS; PSYCHOTIC DISORDERS; TREATMENT OUTCOME;

EID: 84873045013     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-050911-161504     Document Type: Review

References (99)

1. Kane JM, Correll CU. 2010. Past and present progress in the pharmacologic treatment of schizophrenia. J. Clin. Psychiatry 71(9):1115-24
2. Maher AR, Maglione M, Bagley S, et al. 2011. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review andmeta-analysis. JAMA 306(12):1359-69
3. Ban TA. 2007. Fifty years chlorpromazine: a historical perspective. Neuropsychiatr.Dis. Treat. 3(4):495-500
4. Meltzer HY. 2012. Clozapine: balancing safety with superior antipsychotic efficacy. Clin. Schizophr. Relat. Psychoses 6:134-44
5. Kapur S, Remington G. 2001. Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol. Psychiatry 50(11):873-83
6. Meltzer HY, Matsubara S, Lee JC. 1989. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J. Pharmacol. Exp. Ther. 251(1):238-46
7. Marcus MM, Wiker C, Frånberg O, et al. 2010. Adjunctive alpha2-adrenoceptor blockade enhances the antipsychotic-like effect of risperidone and facilitates cortical dopaminergic and glutamatergic, NMDA receptor-mediated transmission. Int. J. Neuropsychopharmacol. 13(7):891-903
8. Meltzer HY. 2000. An atypical compound by any other name is still a. Psychopharmacology (Berlin) 148(1):16-19
9. Lieberman JA, Stroup S, McEvoy JP, et al. 2005. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353(12):1209-23
10. Jones PB, Barnes TR, Davies L, et al. 2006. Randomized controlled trial of the effect on quality of life of second- versus first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch. Gen. Psychiatry 63(10):1079-87
11. Green MF, Kern RS, BraffDL, et al. 2000. Neurocognitive deficits and functional outcome in schizophrenia: Are we measuring the "right stuff "? Schizophr. Bull. 26(1):119-36
12. Gray JA, Roth BL. 2007. Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophr. Bull. 33(5):1100-19
13. Meltzer HY, Stahl SM. 1976. The dopamine hypothesis of schizophrenia: a review. Schizophr. Bull. 2:19-76
14. Uchida H, Takeuchi H, Graff-Guerrero A, et al. 2011. Dopamine D2 receptor occupancy and clinical effects: a systematic review and pooled analysis. J. Clin. Psychopharmacol. 31(4):497-502
15. Meltzer HY. 1985. Long-term effects of neuroleptic drugs on the neuroendocrine system. Adv. Biochem. Psychopharmacol. 40:59-68
16. Bushe C, Shaw M, Peveler RC. 2008. A review of the association between antipsychotic use and hyperprolactinaemia. J. Psychopharmacol. 22(2 Suppl.):46-55
17. Serretti A, Chiesa A. 2011. A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics. Int. Clin. Psychopharmacol. 26(3):130-40
18. Bostwick JR, Guthrie SK, Ellingrod VL. 2009. Antipsychotic-induced hyperprolactinemia. Pharmacotherapy 29(1):64-73
19. Meltzer HY, HuangM. 2008. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Prog. Brain Res. 172:177-97
20. Meltzer HY, Bobo WV. 2009. Antipsychotic and anticholinergic drugs. In New Oxford Textbook of Psychiatry, 2:1208-30. Oxford, UK: Oxford Univ. Press
21. Citrome L. 2011. Iloperidone, asenapine, and lurasidone: a brief overview of three new second-generation antipsychotics. Postgrad. Med. 123(2):153-62
22. Burris KD, Molski TF, Xu C, et al. 2002. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J. Pharmacol. Exp. Ther. 302(1):381-89
23. Meltzer HY. 2012. Serotonergic mechanisms as targets for existing and novel antipsychotics. In Handbook of Experimental Pharmacology, ed. G Gross, M Geyer. Springer Verlag. In press
24. Abbas AI, Hedlund PB, Huang XP, et al. 2009. Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology (Berlin) 205(1):119-28
25. Kiss B, Horváth A, Némethy Z, et al. 2010. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J. Pharmacol. Exp. Ther. 333(1):328-40
26. Butini S, Gemma S, Campiani G, et al. 2009. Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior. J. Med. Chem. 52(1):151-69
27. Neill JC, Barnes S, Cook S, et al. 2010. Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. Pharmacol. Ther. 128(3):419-32
28. Maurel-Remy S, Bervoets K, Millan MJ. 1995. Blockade of phencyclidine-induced hyperlocomotion by clozapine and MDL 100, 907 in rats reflects antagonism of 5-HT2A receptors. Eur. J. Pharmacol. 280(2):R9-11
29. Seeman P. 2010. Dopamine D2 receptors as treatment targets in schizophrenia. Clin. Schizophr. Relat. Psychoses 4(1):56-73
30. Newman-Tancredi A, Kleven MS. 2011. Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties. Psychopharmacology (Berlin) 216(4):451-73
31. Yuen EY, Jiang Q, Chen P, et al. 2005. Serotonin 5-HT1A receptors regulate NMDA receptor channels through a microtubule-dependent mechanism. J. Neurosci. 25(23):5488-501
32. Ichikawa J, Li Z, Dai J, et al. 2002. Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in ratmedial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res. 956(2):349-57
33. Ichikawa J, Dai J, O'Laughlin IA, et al. 2002. Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology 26(3):325-39
34. Sato M, Ago Y, Koda K, et al. 2007. Role of postsynaptic serotonin1A receptors in risperidone-induced increase in acetylcholine release in rat prefrontal cortex. Eur. J. Pharmacol. 559(2-3):155-60
35. Meltzer HY, Horiguchi M, Massey BW. 2011. The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment. Psychopharmacology (Berlin) 213(2-3):289-305
36. Blanc O, Brousse G, Meary A, et al. 2010. Pharmacogenetic of response efficacy to antipsychotics in schizophrenia: pharmacodynamic aspects. Review and implications for clinical research. Fundam. Clin. Pharmacol. 24(2):139-60
37. Kroeze WK, Hufeisen SJ, Popadak BA. 2003. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28(3):519-26
38. Schulte P. 2003. What is an adequate trial with clozapine? Therapeutic drug monitoring and time to response in treatment-refractory schizophrenia. Clin. Pharmacokinet. 42(7):607-18
39. Volavka J. 2012. Clozapine is gold standard, but questions remain. Int. J. Neuropsychopharmacol. 15:1201-4
40. Kane J, Honigfeld G, Singer J, et al. 1988. Clozapine for the treatment-resistant schizophrenia. A doubleblind comparison with chlorpromazine. Arch. Gen. Psychiatry 45(9):789-96
41. Meltzer HY. 1997. Treatment-resistant schizophrenia-the role of clozapine. Curr. Med. Res. Opin. 14(1):1-20
42. Moncrieff J. 2003. Clozapine v. conventional antipsychotic drugs for treatment-resistant schizophrenia: a re-examination. Br. J. Psychiatry 183:161-66
43. Meltzer HY, Bobo WV, Roy A. 2008. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. J. Clin. Psychiatry 69(2):274-85
44. Kane JM, Meltzer HY, Carson WH Jr, et al. 2007. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. Aripiprazole Study Group. J. Clin. Psychiatry 68(2):213-23
45. Braga RJ, Petrides G. 2005. The combined use of electroconvulsive therapy and antipsychotics in patients with schizophrenia. J. ECT 21(2):75-83
46. Meltzer HY, Okayli G. 1995. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am. J. Psychiatry 152(2):183-90
47. Meltzer HY, Alphs L, Green AI, et al. 2003. International Suicide Prevention Trial Study Group. Arch. Gen. Psychiatry 60(1):82-91
48. Kelly TM, Daley DC, Douaihy AB. 2009. Treatment of substance abusing patients with comorbid psychiatric disorders. Addict. Behav. 37(1):11-24
49. Raja M. 2011. Clozapine safety, 35 years later. Curr. Drug Saf. 6(3):164-84
50. Horvitz-LennonM, Donohue JM, DominoME, et al. 2009. Improving quality and diffusing best practices: the case of schizophrenia. Health Aff. (Millwood) 28(3):701-12
51. Tiihonen J, Lönnqvist J, Wahlbeck K, et al. 2009. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 374(9690):620-27
52. Colton CW, Manderscheid RW. 2006. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev. Chronic Dis. 3(2):A42
53. Dettling M, Cascorbi I, Opgen-Rhein C. 2007. Clozapine-induced agranulocytosis in schizophrenic Caucasians: confirming clues for associations with human leukocyte class I and II antigens. Pharmacogenomics J. 7(5):325-32
54. The Parkinson Study Group. 1999. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N. Engl. J. Med. 340(10):757-63
55. Meltzer HY, Kennedy J, Dai J, et al. 1995. Plasma clozapine levels and the treatment of L-DOPA-induced psychosis in Parkinson's disease. A high potency effect of clozapine. Neuropsychopharmacology 12(1):39-45
56. Meltzer HY, Mills R, Revell S, et al. 2010. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of Parkinson's disease psychosis. Neuropsychopharmacology 35(4):881-92
57. Lieberman JA. 2006. Comparative effectiveness of antipsychotic drugs. A commentary on: Cost UtilityOf The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE). Arch. Gen. Psychiatry 63(10):1069-72
58. Tyrer P, Kendall T. 2009. The spurious advance of antipsychotic drug therapy. Lancet 373(9657):4-5
59. Lee MA, Thompson PA, Meltzer HY. 1994. Effects of clozapine on cognitive function in schizophrenia. J. Clin. Psychiatry 55(Suppl. B):82-87
60. Meltzer HY, Bobo WV, Lee MA, et al. 2010. A randomized trial comparing clozapine and typical neuroleptic drugs in non-treatment-resistant schizophrenia. Psychiatry Res. 177(3):286-93
61. Davis JM, Chen N, Glick ID. 2003. A meta-analysis of the efficacy of second-generation antipsychotics. Arch. Gen. Psychiatry 60(6):553-64
62. Geddes J, FreemantleN, Harrison P, et al. 2000. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 321(7273):1371-76
63. Leucht S, Corves C, Arbter D, et al. 2009. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373(9657):31-41
64. Ganguly R, Kotzan JA, Miller LS, et al. 2004. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. J. Clin. Psychiatry 65(10):1377-88
65. Yamin S, Vaddadi K. 2010. Are we using excessive neuroleptics? An argument for systematic neuroleptic dose reduction in stable patients with schizophrenia with specific reference to clozapine. Int. Rev. Psychiatry 22(2):138-47
66. Hogarty GE, Schooler NR, Baker RW. 1997. Efficacy versus effectiveness. Psychiatr. Serv. 48(9):1107
67. Davis JM, Chen N, Glick ID. 2008. Issues that may determine the outcome of antipsychotic trials: industry sponsorship and extrapyramidal side effect. Neuropsychopharmacology 33(5):971-75
68. Kraemer HC, Glick ID, Klein DF. 2009. Clinical trials design lessons from the CATIE study. Am. J. Psychiatry 166(11):1222-28
69. March J, Kraemer HC, Trivedi M, et al. 2010. What have we learned about trial design from NIMHfunded pragmatic trials? Neuropsychopharmacology 35(13):2491-501
70. Glick ID, Correll CU, Altamura AC, et al. 2011. Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach. J. Clin. Psychiatry 72(12):1616-27
71. Meltzer HY, Bobo WV. 2006. Interpreting the efficacy findings in the CATIE study: what clinicians should know. CNS Spectr. 11(7 Suppl. 7):14-24
72. Kinon BJ, Volavka J, Stauffer V, et al. 2008. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study. J. Clin. Psychopharmacol. 28(4):392-400
73. Gerlach J. 1991. New antipsychotics: classification, efficacy, and adverse effects. Schizophr. Bull. 17(2):289-309
74. Robertson GS, Matsumura H, Fibiger HC. 1994. Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J. Pharmacol. Exp. Ther. 271(2):1058-66
75. Kahn RS, Fleischhacker WW, Boter H, et al. 2008. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371(9618):1085-97
76. Tiihonen J, Haukka J, Taylor M, et al. 2011. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am. J. Psychiatry 168(6):603-9
77. Lewis S, Lieberman J. 2008. CATIE and CUtLASS: Can we handle the truth? Br. J. Psychiatry 192(3):161-63
78. Rosenheck RA, Leslie DL, Sindelar J. 2006. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am. J. Psychiatry 163(12):2080-89
79. Rosenheck RA, Leslie DL, Doshi JA. 2008. Second-generation antipsychotics: cost-effectiveness, policy options, and political decision making. Psychiatr. Serv. 59(5):515-20
80. MeltzerDO, Basu A, Meltzer HY. 2009. Comparative effectiveness research for antipsychoticmedications: How much is enough? Health Aff. (Millwood) 28(5):794-808
81. Miller DD, Caroff SN, Davis SM, et al. 2008. Extrapyramidal side-effects of antipsychotics in a randomised trial. Br. J. Psychiatry 193(4):279-88
82. Vinogradov S, Fisher M, Warm H, et al. 2009. The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia. Am. J. Psychiatry 166(9):1055-62
83. Margolese HC, Chouinard G, Kolivakis TT, et al. 2005. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia. Can. J. Psychiatry 50:703-14
84. Correll CU, Leucht S, Kane JM. 2004. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am. J. Psychiatry 161(3):414-25
85. Chong SA, Tay JA, Subramaniam M, et al. 2009. Mortality rates among patients with schizophrenia and tardive dyskinesia. J. Clin. Psychopharmacol. 29(1):5-8
86. Meltzer HY, McGurk SR. 1999. The effect of clozapine, risperidone and olanzapine on cognitive function in schizophrenia. Schiz. Bull. 25:233-55
87. Kales HC, Kim HM, Zivin K, et al. Risk of mortality among individual antipsychotics in patients with dementia. Am. J. Psychiatry 169(1):71-79
88. HaggerC, Buckley P, Kenny JT, et al. 1993. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol. Psychiatry 34(10):702-12
89. Harvey PD, Keefe RS. 2001. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am. J. Psychiatry 158(2):176-84
90. Woodward ND, Purdon SE, Meltzer HY, et al. 2005. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int. J. Neuropsychopharm. 8:457-72
91. Keefe RSE, Bilder RM, Davis SM, et al. 2007. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch. Gen. Psychiatry 64:633-47
92. Bilder RM, Goldman RS, Volavka J, et al. 2002. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am. J. Psychiatry 159(6):1018-28
93. Harvey PD, Sacchetti E, Galluzzo A, et al. 2008. A randomized double-blind comparison of ziprasidone versus clozapine for cognition in patients with schizophrenia selected for resistance or intolerance to previous treatment. Schizophr. Res. 105(1-3):138-43
94. Keedy SK, Rosen C, Khine T, et al. 2009. An fMRI study of visual attention and sensorimotor function before and after antipsychotic treatment in first-episode schizophrenia. Psychiatry Res. 172(1):16-23
95. Amiel JM, Mangurian CV, Ganguli R, et al. 2008. Addressing cardiometabolic risk during treatment with antipsychotic medications. Curr. Opin. Psychiatry 21(6):613-18
96. Meltzer HY, Elkis H, Vanover K, et al. 2012. Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone 2mg/day but does not enhance efficacy of haloperidol 2mg/day: comparison with reference dose risperidone, 6mg/day. Schizophr. Res. 1:144-52
97. Hasnain M, Fredrickson SK, Vieweg WV. 2011. Metformin for obesity and glucose dysregulation in patients with schizophrenia receiving antipsychotic drugs. J. Psychopharmacol. 25(6):715-21
98. KishimotoT, AgarwalV, Kishi T, et al. 2011. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Mol. Psychiatry. doi: 10.1038/mp. 143. Epub ahead of print
99. Kjelby E, Joørgensen HA, Kroken, et al. 2011. Anti-depressive effectiveness of olanzapine, quetiapine, risperidone and ziprasidone: a pragmatic, randomized trial. BMC Psychiatry 11:145